Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Multiple Dose PK of Chiglitazar/Metformin ER in Healthy Volunteers
NCT07511010Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of chiglitazar and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Akeso, Inc. Primary endpoints: Maximum plasma concentration, Area Under the Plasma Concentration-Time Curve and 9 more. Started Sep 2026; status: completed.
02
Drugs
chiglitazarliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07511010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511010.